Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261774 | 0.90 | AKR1C3 (0.53) | LMNAMAPTSMN1; SMN2PTGS2CYP2C19 | |
| SCHEMBL26046551 | 0.89 | CYP2C19 (0.47) | LMNAMAPTHTTSMN1; SMN2PTGS2 | |
| SCHEMBL19403029 | 0.89 | CYP2C19 (0.47) | LMNAMAPTHTTSMN1; SMN2PTGS2 | |
| SCHEMBL12570868 | 0.87 | AKR1C3 (0.50) | LMNAMAPTSMN1; SMN2PTGS2CYP2C19 | |
| SCHEMBL765486 | 0.84 | CYP2C19 (0.68) | LMNAMAPTPTGS2CYP2C19APP | |
| SCHEMBL2739316 | 0.83 | AKR1C3 (0.68) | LMNAMAPTHTTSMN1; SMN2PTGS2 | |
| SCHEMBL14406016 | 0.82 | CYP2C19 (0.47) | LMNAMAPTSMN1; SMN2PTGS2CYP2C19 | |
| SCHEMBL12263203 | 0.81 | AKR1C3 (0.51) | LMNAMAPTPTGS2CYP2C19APP | |
| SCHEMBL26046612 | 0.81 | AKR1C3 (0.42) | LMNAMAPTHTTSMN1; SMN2PTGS2 | |
| SCHEMBL21267584 | 0.81 | APP (0.46) | LMNAMAPTSMN1; SMN2PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616037-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2017-04-11 | — | — | US | disclosed |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-9302984-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| US-9050329-B1 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8435968-B2 | Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use | PIMCO 2664 LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172189-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | LMNA 3996/4885MAPT 1117/4885HTT 2591/4885 |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | LMNA 3777/4885MAPT 53/4885HTT 56/4885 |
| US-20150141472-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | LMNA 3965/4885MAPT 1161/4885HTT 2680/4885 |
| US-20150266815-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | LMNA 3965/4885MAPT 1161/4885HTT 2680/4885 |
| US-20160206578-A1 | Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use | SOST, AADAC, ARSA | LMNA 3965/4885MAPT 1161/4885HTT 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.